{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:56:21Z","timestamp":1793336181024,"version":"4.5.0"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbrc.2025.152822","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:36:41Z","timestamp":1760661401000},"page":"152822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance"],"prefix":"10.1016","volume":"789","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-8102","authenticated-orcid":false,"given":"Murtala A","family":"Ngabea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-5554","authenticated-orcid":false,"given":"Igbayilola Yusuff","family":"Dimeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152822_bib1","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0245","article-title":"Sex-based differences in insulin resistance","volume":"261","author":"Gado","year":"2024","journal-title":"J. Endocrinol."},{"issue":"48","key":"10.1016\/j.bbrc.2025.152822_bib2","doi-asserted-by":"crossref","first-page":"18273","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib3","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2009-1030","article-title":"Ethnic variation in fat and lean body mass and the association with insulin resistance","volume":"94","author":"Lear","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","article-title":"The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia","volume":"33","author":"Sylow","year":"2021","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/joim.12540","article-title":"Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids","volume":"280","author":"Smith","year":"2016","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/ijms24032142","article-title":"Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD","volume":"24","author":"Xie","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1146\/annurev-biochem-060608-102511","article-title":"Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease","volume":"80","author":"Hart","year":"2011","journal-title":"Annu. Rev. Biochem."},{"issue":"7910","key":"10.1016\/j.bbrc.2025.152822_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41586-022-04756-4","article-title":"Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency","volume":"605","author":"Chen","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgae357","article-title":"Hepatocyte MMP14 mediates liver and inter-organ inflammatory responses to diet-induced liver injury","volume":"3","author":"Kelly","year":"2024","journal-title":"PNAS Nexus"},{"issue":"Suppl 1","key":"10.1016\/j.bbrc.2025.152822_bib10","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.4103\/2230-8210.94259","article-title":"Pleiotropic effects of incretins","volume":"16","author":"Gupta","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib11","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/nar\/14.12.4719","article-title":"Structure of the human glucagon gene","volume":"14","author":"White","year":"1986","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib12a","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib12b","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/JOE-11-0328","article-title":"GLP1-derived nonapeptide GLP1(28\u201336) amide protects pancreatic beta-cells from glucolipotoxicity","volume":"213","author":"Brindamour","year":"2012","journal-title":"J. Endocrinol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152822_bib13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.15077","article-title":"New insights into the treatment of obesity","volume":"25","author":"Bl\u00fcher","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152822_bib14","article-title":"Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment","author":"ensen","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabet. Endocrinol."},{"issue":"22","key":"10.1016\/j.bbrc.2025.152822_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114214","article-title":"Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents","volume":"233","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152822_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101801","article-title":"Results from three phase 1 trials of NNC9204-1177, a glucagon\/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity","volume":"78","author":"Friedrichsen","year":"2023","journal-title":"Mol. Metabol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.apsb.2023.11.020","article-title":"Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis","volume":"14","author":"Zhao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib20","doi-asserted-by":"crossref","first-page":"197a","DOI":"10.1016\/j.bpj.2022.11.1202","article-title":"Sequence-based knowledge driven structural design of peptide drugs as co-agonists of GLP-1\/GCG receptors","volume":"122","author":"Vishnoi","year":"2023","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbrc.2025.152822_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.physbeh.2018.03.004","article-title":"Novel GLP-1\/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice","volume":"192","author":"Wismann","year":"2018","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbrc.2025.152822_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mehy.2016.08.005","article-title":"Peptide-based GLP-1\/glucagon co-agonists: a double-edged sword to combat diabesity","volume":"95","author":"Soni","year":"2016","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbrc.2025.152822_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.bbrc.2025.152822_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/802078","article-title":"The role of adipose tissue and adipokines in obesity-related inflammatory diseases","volume":"2010","author":"Balistreri","year":"2010","journal-title":"Mediat. Inflamm."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib25","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"19","key":"10.1016\/j.bbrc.2025.152822_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3390\/cells13191662","article-title":"Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment","volume":"13","author":"Pellegrini","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2025.152822_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.bbrc.2025.152822_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib30","article-title":"Unlocking the multifaceted roles of GLP-1: physiological functions and therapeutic potential","volume":"14","author":"Al-Noshokaty","year":"2025","journal-title":"Toxicol. Rep."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib31","first-page":"3573","article-title":"Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway","volume":"17","author":"Wan","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152822_bib33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/metabo14100554","article-title":"Liraglutide therapy in Obese patients alters macrophage phenotype and decreases their tumor necrosis factor alpha release and oxidative stress Markers-A pilot study","volume":"14","author":"Bu\u0142dak","year":"2024","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/biomedicines13051128","article-title":"GLP-1R agonists and their therapeutic potential in inflammatory bowel disease and other immune-mediated inflammatory diseases, a systematic review of the literature","volume":"13","author":"Thin","year":"2025","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib35","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini","year":"2023","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.bbrc.2025.152822_bib36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front. Physiol."},{"issue":"38","key":"10.1016\/j.bbrc.2025.152822_bib37","doi-asserted-by":"crossref","first-page":"36916","DOI":"10.1074\/jbc.M301598200","article-title":"Tumor necrosis factor-\u03b1-induced IKK phosphorylation of NF-\u03baB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway","volume":"278","author":"Sakurai","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbadis.2013.05.017","article-title":"Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance","volume":"1842","author":"Lee","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/oby.2010.200","article-title":"FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKK\u03b2 pathways","volume":"19","author":"Jiao","year":"2011","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib41","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.2337\/db11-0275","article-title":"Targeting curcusomes to inflammatory dendritic cells inhibits NF-\u03baB and improves insulin resistance in obese mice","volume":"60","author":"Yekollu","year":"2011","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib42","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db09-0232","article-title":"FoxO1 links insulin resistance to proinflammatory cytokine IL-1\u03b2 production in macrophages","volume":"58","author":"Su","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.152822_bib43","article-title":"Mechanisms linking inflammation to insulin resistance","volume":"2015","author":"Chen","year":"2015","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib45","article-title":"Zuonin B inhibits lipopolysaccharide-induced inflammation via downregulation of the ERK1\/2 and JNK pathways in RAW264.7 macrophages","volume":"2012","author":"Lee","year":"2012","journal-title":"Evid Bas. Compl. Alternat. Med."},{"issue":"6116","key":"10.1016\/j.bbrc.2025.152822_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1126\/science.1227568","article-title":"JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation","volume":"339","author":"Han","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054247","article-title":"Alteration of JNK-1 signaling in skeletal muscle fails to affect glucose homeostasis and obesity-associated insulin resistance in mice","volume":"8","author":"Pal","year":"2013","journal-title":"PLoS One"},{"issue":"44","key":"10.1016\/j.bbrc.2025.152822_bib48","doi-asserted-by":"crossref","first-page":"45803","DOI":"10.1074\/jbc.M406963200","article-title":"Modulation of the JNK pathway in liver affects insulin resistance status","volume":"279","author":"Nakatani","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152822_bib49","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.2337\/db12-1097","article-title":"In vivo JNK activation in pancreatic \u03b2-cells leads to glucose intolerance caused by insulin resistance in pancreas","volume":"62","author":"Lanuza-Masdeu","year":"2013","journal-title":"Diabetes"},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2025.152822_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11010-013-1680-0","article-title":"The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE\/JNK\/NF-\u03baB pathway","volume":"380","author":"Wu","year":"2013","journal-title":"Mol. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib51","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.fct.2012.02.029","article-title":"Monascus-fermented metabolite monascin suppresses inflammation via PPAR-\u03b3 regulation and JNK inactivation in THP-1 monocytes","volume":"50","author":"Hsu","year":"2012","journal-title":"Food Chem. Toxicol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152822_bib52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3727\/096368910X550170","article-title":"The sequential combination of a JNK inhibitor and simvastatin protects porcine islets from peritransplant apoptosis and inflammation","volume":"20","author":"Jin","year":"2011","journal-title":"Cell Transplant."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152822_bib53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cmet.2009.09.007","article-title":"Prevention of steatosis by hepatic JNK1","volume":"10","author":"Sabio","year":"2009","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/13813455.2012.713366","article-title":"Contribution of the serine kinase c-Jun N-terminal kinase (JNK) to oxidant-induced insulin resistance in isolated rat skeletal muscle","volume":"118","author":"Santos","year":"2012","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.bbrc.2025.152822_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","article-title":"Mechanisms of disease: inflammasome activation and the development of type 2 diabetes","volume":"4","author":"Grant","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"issue":"17","key":"10.1016\/j.bbrc.2025.152822_bib58","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152822_bib60","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1474-4422(16)30358-1","article-title":"Pain in amyotrophic lateral sclerosis","volume":"16","author":"Kiernan","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbrc.2025.152822_bib62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: a new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J. Orthop. Translat."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib63","first-page":"11","article-title":"Anti-Inflammatory and anti-oxidative effects of GLP1-RAs and SGLT2i: the guiding star towards cardiovascular protection in type 2 diabetes","volume":"5","author":"Marcon","year":"2025","journal-title":"Immunology"},{"key":"10.1016\/j.bbrc.2025.152822_bib64","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbrc.2025.152822_bib65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbrc.2025.152822_bib66","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.152822_bib67","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-010-1831-8","article-title":"A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells","volume":"53","author":"Hattori","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbrc.2025.152822_bib68","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2025.152822_bib69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13205-024-04202-4","article-title":"NF-\u03baB signaling is the major inflammatory pathway for inducing insulin resistance","volume":"15","author":"Mobeen","year":"2025","journal-title":"3 Biotech"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib72","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph18050614","article-title":"Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of alzheimer's disease","volume":"18","author":"Urkon","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.152822_bib73","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1669685","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni","year":"2025","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152822_bib76","article-title":"Glucagon-Like Peptide-1 (GLP-1) receptor agonist use and inflammatory markers among U.S. adults: a national health and nutrition examination survey (NHANES)-based analysis","volume":"17","author":"Youkhana","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2025.152822_bib77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10517-021-05191-7","article-title":"Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction","volume":"171","author":"Darenskaya","year":"2021","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib78","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1038\/s41598-017-06712-z","article-title":"GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.152822_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117531","article-title":"Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats","volume":"250","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib80","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.2174\/1389557521666210422114909","article-title":"Role of GLP-1 analogs in the management of diabetes and its secondary complication","volume":"21","author":"Sivakumar","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152822_bib81","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib82","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fphar.2020.00805","article-title":"Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway","volume":"11","author":"Nuamnaichati","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152822_bib83","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3892\/ijmm.2013.1475","article-title":"Cardioprotective effects of exenatide against oxidative stress-induced injury","volume":"32","author":"Chang","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib84a","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110218","article-title":"Downregulation of the GLP-1\/CREB\/adiponectin pathway is partially responsible for diabetes-induced dysregulated vascular tone and VSMC dysfunction","volume":"127","author":"Xiong","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.152822_bib84b","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1210\/me.2014-1346","article-title":"Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes","volume":"29","author":"Mangmool","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ajpath.2012.09.016","article-title":"Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression","volume":"182","author":"Ojima","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib86","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1210\/me.2014-1346","article-title":"Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes","volume":"29","author":"Mangmool","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6518221","article-title":"The effects of glucagon-like Peptide-1 receptor agonists and Dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.bbrc.2025.152822_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100185","article-title":"Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet","volume":"6","author":"Touceda","year":"2024","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152822_bib89","doi-asserted-by":"crossref","DOI":"10.31083\/RCM37180","article-title":"Research progress on the Association between GLP-1 receptor agonists and cardiomyopathy","volume":"26","author":"Yang","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib90","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2025.152822_bib91","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2025.152822_bib92","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-like peptide-1: glucose homeostasis and beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Annu. Rev. Physiol."},{"issue":"Suppl 3","key":"10.1016\/j.bbrc.2025.152822_bib93","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.152822_bib94","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1152\/physrev.00001.2005","article-title":"PKA-dependent and PKA-Independent pathways for cAMP-regulated exocytosis","volume":"85","author":"Seino","year":"2005","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbrc.2025.152822_bib95","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/361362a0","article-title":"Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7\u201337)","volume":"361","author":"Holz","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.152822_bib96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1113\/jphysiol.2006.107391","article-title":"cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic \u03b2 cells and rat INS-1 cells","volume":"573","author":"Kang","year":"2006","journal-title":"J Physiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib97","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1210\/me.2002-0084","article-title":"Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism","volume":"16","author":"Light","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib98","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.2337\/diabetes.51.12.3440","article-title":"cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets","volume":"51","author":"Nakazaki","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.152822_bib99","doi-asserted-by":"crossref","first-page":"37176","DOI":"10.1074\/jbc.M206757200","article-title":"Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose","volume":"277","author":"Shiota","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152822_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/bbrc.1995.1149","article-title":"Glucagon-like peptide-1 modulates Ca2+ current but not KATP current in intact mouse pancreatic \u03b2-cells","volume":"207","author":"Britsch","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152822_bib101","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1210\/endo.133.4.8404610","article-title":"Glucagon-like peptide-1-(7\u201336) amide and a rise in cyclic adenosine 3\u2019, 5\u2019-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity","volume":"133","author":"Yada","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbrc.2025.152822_bib102","first-page":"17987","article-title":"Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin","volume":"270","author":"Holz","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152822_bib103","doi-asserted-by":"crossref","first-page":"17987","DOI":"10.1074\/jbc.272.29.17987","article-title":"Insulinotropic glucagon-like peptide-1-mediated activation of non-selective cation currents in insulinoma cells is mimicked by maitotoxin","volume":"272","author":"Leech","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2025.152822_bib104","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cmet.2011.02.001","article-title":"Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation","volume":"13","author":"Hayes","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152822_bib173","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1080\/21655979.2022.2036902","article-title":"Liraglutide inhibits receptor for advanced glycation end products (RAGE)\/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro","volume":"13","author":"Ji","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbrc.2025.152822_bib147","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2019.01.055","article-title":"Toll-like receptor 4 is necessary for glucose-dependent glucagon-like peptide-1 secretion in male mice","volume":"510","author":"Wang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152822_bib175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1074248420942007","article-title":"Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-Mediated ROS production in hypertensive mice","volume":"26","author":"Chen","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.bbrc.2025.152822_bib176","doi-asserted-by":"crossref","first-page":"555","DOI":"10.17219\/acem\/133483","article-title":"Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis","volume":"30","author":"Yang","year":"2021","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib177","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdi.13098","article-title":"Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamy cin complex 1\/p70 ribosomal protein S6 kinase pathway in diabetes mellitus","volume":"11","author":"Wang","year":"2020","journal-title":"J. Diabet. Investig."},{"key":"10.1016\/j.bbrc.2025.152822_bib143","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000539278","article-title":"Pattern-recognition receptors and immunometabolic reprogramming: what we know and what to explore","volume":"16","author":"Kumar","year":"2024","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.bbrc.2025.152822_bib178","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fendo.2019.00202","article-title":"Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart","volume":"10","author":"Ding","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib179","doi-asserted-by":"crossref","DOI":"10.1038\/srep41085","article-title":"Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway","volume":"7","author":"Ke","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.152822_bib105","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1080\/21655979.2022.2036902","article-title":"Liraglutide inhibits receptor for advanced glycation end products (RAGE)\/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro","volume":"13","author":"Ji","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.bbrc.2025.152822_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670389","article-title":"Sitagliptin reduces endothelial dysfunction and apoptosis induced by high-fat diet and palmitate in thoracic aortas and endothelial cells via ROS-ER Stress-CHOP pathway","volume":"12","author":"Cao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152822_bib107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1074248420942007","article-title":"Liraglutide attenuates myocardial fibrosis via inhibition of AT1R-Mediated ROS production in hypertensive mice","volume":"26","author":"Chen","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.bbrc.2025.152822_bib108","doi-asserted-by":"crossref","first-page":"555","DOI":"10.17219\/acem\/133483","article-title":"Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis","volume":"30","author":"ang","year":"2021","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdi.13098","article-title":"Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamy cin complex 1\/p70 ribosomal protein S6 kinase pathway in diabetes mellitus","volume":"11","author":"Wang","year":"2020","journal-title":"J. Diabet. Investig."},{"key":"10.1016\/j.bbrc.2025.152822_bib110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fendo.2019.00202","article-title":"Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart","volume":"10","author":"Ding","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/srep41085","article-title":"Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway","volume":"7","author":"Ke","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2025.152822_bib112","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib114","first-page":"1","article-title":"Anti-inflammatory effects of GLP-1-Based therapies beyond glucose control","volume":"11","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbrc.2025.152822_bib115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/ars.2016.6664","article-title":"Diabetes and kidney disease: role of oxidative stress","volume":"25","author":"Jha","year":"2016","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.bbrc.2025.152822_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib117","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbrc.2025.152822_bib118","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdi.12063","article-title":"Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes","volume":"4","author":"He","year":"2013","journal-title":"J. Diabet. Invest."},{"key":"10.1016\/j.bbrc.2025.152822_bib119","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc12-2469","article-title":"Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes","volume":"36","author":"Ceriello","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2025.152822_bib120","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/dia.2011.0076","article-title":"Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies","volume":"13","author":"Stonehouse","year":"2011","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.bbrc.2025.152822_bib121","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152822_bib122","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2337\/dc20-0498","article-title":"Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis","volume":"43","author":"Huthmacher","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2025.152822_bib123","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/dom.13761","article-title":"Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"21","author":"Anholm","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152822_bib124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cbi.2018.01.004","article-title":"Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition","volume":"282","author":"Patel","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bbrc.2025.152822_bib125","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbrc.2025.152822_bib126","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11883-022-01041-7","article-title":"Glucagon-like peptide 1 receptor agonists: a medication for obesity management","volume":"24","author":"Taha","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.bbrc.2025.152822_bib127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.bbrc.2025.152822_bib128","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib129","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/iub.2046","article-title":"The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2","volume":"71","author":"Yue","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbrc.2025.152822_bib130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib131","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib132","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4274\/balkanmedj.galenos.2023.2023-8-44","article-title":"The key role of liraglutide in preventing autophagy of vascular smooth muscle cells in high glucose conditions","volume":"41","author":"Shi","year":"2024","journal-title":"Balkan Med. J."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152822_bib133","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of GLP-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib134","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70082","article-title":"Efficacy of GLP-1 receptor agonist-based therapies on cardiovascular events and cardiometabolic parameters in obese individuals without diabetes: a meta-analysis of randomized controlled trials","volume":"17","author":"Yin","year":"2025","journal-title":"J. Diabetes"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib135","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.bbrc.2025.152822_bib136","article-title":"Gut microbiota: a new target for T2DM prevention and treatment","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152822_bib137","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240303","article-title":"GLP-1\/GLP-1R axis: from metabolism (obesity and T2DM) to immunity","volume":"15","author":"Kumar","year":"2025","journal-title":"Open Biol."},{"key":"10.1016\/j.bbrc.2025.152822_bib138","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1113\/JP286258","article-title":"Lipopolysaccharide accelerates peristalsis by stimulating glucagon-like peptide-1 release from L cells in the rat proximal colon","volume":"602","author":"Nakamori","year":"2024","journal-title":"J. Physiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri1747","article-title":"Signalling pathways and molecular interactions of NOD1 and NOD2","volume":"6","author":"Strober","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.biochem.74.082803.133347","article-title":"NOD-LRR proteins: role in host-microbial interactions and inflammatory disease","volume":"74","author":"Inohara","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2025.152822_bib141","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/mi.2011.29","article-title":"NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease","volume":"4","author":"Strober","year":"2011","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib142","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.3390\/ijms21155252","article-title":"The role of the bacterial muramyl dipeptide in the regulation of GLP-1 and glycemia","volume":"21","author":"Williams","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152822_bib144","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ni.2635","article-title":"Innate immune recognition of the microbiota promotes host-microbial symbiosis","volume":"14","author":"Chu","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri3430","article-title":"Role of the gut microbiota in immunity and inflammatory disease","volume":"13","author":"Kamada","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib146","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","article-title":"Epithelial Toll-like receptors and their role in gut homeostasis and disease","volume":"17","author":"Burgue\u00f1o","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2025.152822_bib148","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cmet.2017.03.021","article-title":"Muramyl dipeptide-based postbiotics mitigate obesity-induced insulin resistance via IRF4","volume":"25","author":"Cavallari","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbrc.2025.152822_bib149","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/156800906776056473","article-title":"Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma","volume":"6","author":"Nardin","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bbrc.2025.152822_bib150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib151","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbrc.2025.152822_bib152","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0043-109563","article-title":"Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes","volume":"49","author":"Iacobellis","year":"2017","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bbrc.2025.152822_bib153","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2019.04.039","article-title":"Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk?","volume":"292","author":"Dozio","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib154","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145495","article-title":"Obesity and diabetes are major risk factors for epicardial adipose tissue inflammation","volume":"6","author":"Vyas","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2025.152822_bib156","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/j.2040-4603.2017.tb00767.x","article-title":"Role of epicardial adipose tissue in health and disease: a matter of fat?","volume":"7","author":"Gaborit","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.bbrc.2025.152822_bib157","first-page":"1013","article-title":"Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro","volume":"14","author":"Marchington","year":"1990","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.bbrc.2025.152822_bib158","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2327341","article-title":"Expression of the receptor for advanced glycation end products in epicardial fat: link with tissue thickness and local insulin resistance in coronary artery disease","volume":"2016","author":"Dozio","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.bbrc.2025.152822_bib159","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1615\/CritRevImmunol.v18.i3.40","article-title":"Intraepithelial lymphocytes: origins, distribution, and function","volume":"18","author":"Beagley","year":"1998","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41385-020-0294-6","article-title":"Mechanisms of activation of innate-like intraepithelial T lymphocytes","volume":"13","author":"Vandereyken","year":"2020","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib161","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/s41385-018-0016-5","article-title":"Human intraepithelial lymphocytes","volume":"11","author":"Mayassi","year":"2018","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib162","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/JLB.3RU0220-111","article-title":"Intestinal intraepithelial lymphocytes: maintainers of intestinal immune tolerance and regulators of intestinal immunity","volume":"109","author":"Ma","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbrc.2025.152822_bib163","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-immunol-090222-100246","article-title":"Intraepithelial lymphocytes of the intestine","volume":"42","author":"Lockhart","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib164","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nri3007","article-title":"The light and dark sides of intestinal intraepithelial lymphocytes","volume":"11","author":"Cheroutre","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib165","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.bbrc.2025.152822_bib166","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-018-0849-9","article-title":"Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease","volume":"566","author":"He","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.152822_bib167","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1172\/JCI42497","article-title":"Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice","volume":"122","author":"Lamont","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2025.152822_bib168","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1084\/jem.193.4.497","article-title":"Activation of the Cooh-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor","volume":"193","author":"Vang","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2025.152822_bib169","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/cimm.1996.0274","article-title":"Elevation of intracellular cyclic AMP induces an anergic-like state in Th1 clones","volume":"173","author":"Cone","year":"1996","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bbrc.2025.152822_bib170","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2741\/2022","article-title":"Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts","volume":"11","author":"Tasken","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbrc.2025.152822_bib171","first-page":"301","article-title":"cAMP-mediated suppression of a Th1 clone associated with an alteration of the intracellular redox environment","volume":"49","author":"Cochrane","year":"2003","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.bbrc.2025.152822_bib172","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12933-018-0701-4","article-title":"Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes","volume":"17","author":"Chen","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib181","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02237-8","article-title":"Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus","volume":"23","author":"Grannes","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbrc.2025.152822_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: double-edged sword with risks and benefits","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Arch Intern. Med. Res."},{"issue":"11","key":"10.1016\/j.bbrc.2025.152822_bib184","doi-asserted-by":"crossref","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib185","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review","volume":"15","author":"Parab","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2025.152822_bib186","article-title":"Anti-inflammatory benefits of semaglutide: state of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib187","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/gtc.13098","article-title":"The anti-inflammatory effect of metformin: the molecular targets","volume":"29","author":"Sakata","year":"2024","journal-title":"Genes Cells"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib188","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbrc.2025.152822_bib189","article-title":"Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus","volume":"2014","author":"Li","year":"2014","journal-title":"Evid Bas. Compl. Alternat. Med."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/ph18020279","article-title":"Natural bioactive compounds in the management of type 2 diabetes and metabolic (Dysfunction)-associated steatotic liver disease","volume":"18","author":"Ciob\u00e2rc\u0103","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.152822_bib191","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metabol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib192","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/biomedicines13030728","article-title":"Targeting diabetic atherosclerosis: the role of GLP-1 receptor agonists, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists in vascular protection and disease modulation","volume":"13","author":"Rroji","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib193","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol. Therapeut."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib194","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"9861","key":"10.1016\/j.bbrc.2025.152822_bib195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib196","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4)","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib197","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib198","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","article-title":"Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis","volume":"29","author":"Buse","year":"2007","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad. Med. J."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib200","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide-1\u2013induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib201","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7)","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib202","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1)","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152822_bib203","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib204","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9)","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"19","key":"10.1016\/j.bbrc.2025.152822_bib205","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib206","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"Pioneer 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"10192","key":"10.1016\/j.bbrc.2025.152822_bib207","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4)","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152822_bib208","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin (PIONEER 8)","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.bbrc.2025.152822_bib209","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.152822_bib210","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbrc.2025.152822_bib211","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/230624","article-title":"Impact of GLP-1 receptor agonists on major gastrointestinal disorders in type 2 diabetes: a mixed treatment comparison meta-analysis","volume":"2012","author":"Sun","year":"2012","journal-title":"Exp. Diabetes Res."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152822_bib212","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.bbrc.2025.152822_bib213","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s13300-021-01140-9","article-title":"Gastrointestinal tolerability of once-weekly dulaglutide 3.0 mg and 4.5 mg: post hoc analysis of AWARD-11","volume":"12","author":"Van","year":"2021","journal-title":"Diabetes Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib214","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/diaclin.32.1.32","article-title":"Optimizing the care of patients with type 2 diabetes using incretin-based therapy: focus on GLP-1 receptor agonists","volume":"32","author":"Shomali","year":"2014","journal-title":"Clin. Diabetes"},{"issue":"6","key":"10.1016\/j.bbrc.2025.152822_bib215","article-title":"Corrination of a GLP-1 receptor agonist for glycemic control without emesis","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Rep."},{"issue":"2\u20133","key":"10.1016\/j.bbrc.2025.152822_bib216","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000094334","article-title":"Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion"},{"issue":"6","key":"10.1016\/j.bbrc.2025.152822_bib217","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152822_bib218","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/2050640620925968","article-title":"Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: a randomized, placebo-controlled trial","volume":"8","author":"Wegeberg","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib219","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int. J. Obes."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152822_bib220","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss regardless of baseline BMI or gastrointestinal adverse events (SUSTAIN 1\u20135)","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib221","article-title":"Superior weight loss with once-weekly semaglutide versus other GLP-1RAs is independent of gastrointestinal adverse events","volume":"8","author":"Lingvay","year":"2020","journal-title":"BMJ Open Diabet. Res Care"},{"issue":"13","key":"10.1016\/j.bbrc.2025.152822_bib222","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152822_bib223","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dom.16136","article-title":"Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: a systematic review","volume":"27","author":"Wong","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.bbrc.2025.152822_bib224","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.bbrc.2025.152822_bib226","series-title":"Heart, Lung and Circulation","article-title":"Established and emerging therapies for cardiovascular\u2013kidney\u2013metabolic syndrome: harnessing the benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and beyond","author":"Allahwala","year":"2025"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152822_bib227","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s43032-025-01788-9","article-title":"Comparison of GLP-1 receptor agonists combined with metformin versus metformin alone in the management of PCOS: a comprehensive meta-analysis","volume":"32","author":"Zhao","year":"2025","journal-title":"Reprod. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib228","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152822_bib229","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152822_bib230","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13300-020-00855-5","article-title":"Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update","volume":"11","author":"Hanefeld","year":"2020","journal-title":"Diabetes Ther."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152822_bib231","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152822_bib232","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J. Clin. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25015384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25015384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:20:12Z","timestamp":1780906812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25015384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":231,"alternative-id":["S0006291X25015384"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152822","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152822"}}